OBLON
SPIVAK
McCLELLAND
MAIER
&
NEUSTADT
BC.

FACSIMILE

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

August 12, 2002 Examiner Sonya N. Wright TO DATE NAME ATTORNEYS AT LAW 703-308**-**7922 U.S. Patent & Trademark Office FAX # COMPANY/FIRM FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 CONFIRM FAX: ☐YES
☐NO NUMBER OF PAGES INCLUDING COVER: _ Vincent K. Shier, Ph.D. (703) 413-3000 210100US0PCT Registration No. 50,552 FROM (703) 413-2220 FACSIMILE **OUR REFERENCE** NAME 09/868,894 703-413-3000 OBLONPAT@OBLON.COM YOUR REFERENCE DIRECT PHONE # PATENT, TRADEMARK AND COPYRIGHT LAW AND RELATED FEDERAL AND ITC LITIGATION

WWW.QBLQN.COM

MESSAGE

Examiner Wright,

Per our discussion this afternoon, attached is an excerpt from Applicant's instructions. Please let me know if these are acceptable or if further election is necessary.

With best regards,

Vince

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

NO. 047 F. 2

DOCKET NO.: 210100US0PCT

SERIAL NO.:

09/868,894

"As to the restriction requirement, we would like to elect the following embodiment (A) among the embodiments (A) to (C), which were drafted by us.

Applicant's Specific Embodiment

(A) Claims 1-17, drawn to compounds in formula (I) wherein

R1 is as defined, (namely, lower alkyl, halogen, optionally substituted hererocyclic group or optionally substituted aryl)

R2 is as defined, (namely, carboxy, protected carboxy or amidated carboxy)

Ar is optionally substituted heterocyclic group, (preferably thienyl)

A is as defined, (namely, lower alkylene)

X is as defined, (namely, oxa or a single bond)

Y is as defined, (namely, thia, sulfinyl or sulfonyl)

Z is methylene, and

m and n are as defined.

(B) Claims 1-17, drawn to compoounds in formula (I) wherein

R1 is as defined, (namely, lower alkyl, halogen, optionally substituted heterocyclic group or optionally substituted aryl)

R2 is as defined, (namely, carboxy, protected carboxy or amidated carboxy)

Ar is optionally substituted aryl, (preferably phenyl)

A is as defined, (namely, lower alkylene)

X is as defined, (namely, oxa or a single bond)

Y is as defined, (namely, thia, sulfinyl or sulfonyl)

Z is methylene, and

m and n are as defined.

(C) And other minor compounds.

We believe that each embodiment (A)/(B) satisfies the criteria for unity of invention.

Nevertheless, if the above embodiment (A) is not accepted by the Examiner, we are ready to restrict the definition of embodiment (A) to a narrow one, wherein X is a single bond, and/or Y is sulfonyl, and the like."